135 results about "Lidocaine" patented technology

There is provided methods for insect control, including controlling myiasis, in animals by affixing to the animal an elastomeric band having infused or contained within an insecticide, an insect repellant, lidocaine, or any combination thereof. The insect control may be a dual-mode control and may be in respect of existing or impending open wounds, including open wounds caused by castration, tail docking, umbilical cord ligation, or dehorning of an animal. There is also provided methods for castration, docking, umbilical cord ligation, or dehorning of an animal with concurrent insect control. Also provided are elastomeric bands for insect control and methods for preparing such elastomeric bands.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a riptacaine cream as well as a preparation method and application thereof, and the preparation method of the riptacaine cream comprises the following steps: preparing carbomer gel, preparing an oil phase, preparing a water phase, primarily emulsifying, homogenizing and gelating, finely homogenizing and filling. According to the invention, polyoxyethylene (54) hydrogenated castor oil is innovatively used as an auxiliary material, triple functions of a co-melting solvent, an emulsifying agent and a stabilizing agent are realized at the same time, and any liquid grease, solvent or other surfactants do not need to be additionally added in the prescription. Through a unique'water-gel-oil 'composite structure design, oil drops are physically wrapped by a carbomer gel network and are positioned in network pores, so that the mechanical stability superior to that of a conventional emulsion is provided, and no layering is generated through high-speed centrifugal test verification. In conclusion, the invention develops the riptacaine preparation which has the advantages of few types of auxiliary materials, higher stability, quicker effect taking and capability of expanding a new dosage form and a new process.

A drug resistant film is provided. The drug resistant film includes a drug contact sealing layer, an aluminum foil layer, a biaxially oriented polyamide layer, and a paper layer. The drug contact layer is configured to contact a drug, such as lidocaine, nicotine, or fentanyl. The aluminum foil layer is affixed to the drug contact sealing layer via a first lamination adhesive. The biaxially oriented polyamide layer is affixed to the aluminum foil layer via a second lamination adhesive. The paper layer is affixed to the biaxially orientated polyamide layer via a third lamination adhesive. According to an example, the drug contact sealing layer comprises an extruded monolayer of COC, EVOH, or PETG. According to an example, the drug contact sealing layer is a coextruded layer comprising a plurality of sublayers.

The invention relates to lidocaine multivesicular liposome as well as a preparation method and application thereof, belongs to the field of medicines, and solves at least one of the problems of higher toxicity, insufficient safety, short action time, limited clinical application range, higher cost and the like of the existing postoperative analgesic medicine. The lidocaine multi-vesicular liposome is prepared from lidocaine and a lipid, wherein the lidocaine and the lipid are added into the lidocaine multi-vesicular liposome; the lipid comprises amphiphilic lipid, negatively charged phospholipid, neutral lipid and cholesterol. The lidocaine multi-vesicular liposome prepared by the preparation method is high in safety, solves the problems of systemic toxicity, neurotoxicity, cardiotoxicity and the like of the existing postoperative analgesic drugs, has the characteristics of long-acting slow release, remarkable analgesic effect and wide clinical application range, and is suitable for clinical application. And a new solution is provided for effectively relieving postoperative pain.

The invention relates to the technical field of organ transplantation, and discloses organ preserving fluid, application and organ dynamic supercooling perfusion equipment. The organ preserving fluid is prepared from ribose, glucose, mannitol, lidocaine, adenosine, a high-molecular polymer, L-proline, trehalose, inorganic salt and organic salt. The high-molecular polymer comprises one of hydroxyethyl starch, polyethylene glycol and albumin. According to the organ preserving fluid disclosed by the invention, the freezing point of the perfusate is reduced through the micromolecular cryoprotectant, and meanwhile, the micromolecular cryoprotectant and the high-molecular polymer jointly inhibit formation and growth of ice crystals; the problem of liquid preservation at the temperature below zero is solved from the two dimensions of physics (reducing the freezing point and inhibiting ice crystals) and biology (maintaining cell viability), and feasibility is provided for long-time low-temperature transfer and transplantation of organs. The preserving fluid can be used for static preservation or perfusion preservation of various organs such as kidney, liver, heart, pancreas, lung, small intestine, skin and the like.

The utility model relates to an adjustable fixable perineum cold patch which comprises a metering type nursing pad and a medicine pad, the medicine pad is arranged at the position, corresponding to the perineum of a puerpera, of the metering type nursing pad, an adjustable fastening structure is arranged on the metering type nursing pad and used for firmly wearing the metering type nursing pad, and the medicine pad comprises a sanitary towel and an adhesive area. Liquid medicine is adsorbed on the front face of the sanitary towel, an adhesive area is arranged on the back face of the sanitary towel, the sanitary towel adheres to the metering type nursing pad through the adhesive area on the back face of the sanitary towel, and the liquid medicine is prepared from magnesium sulfate, normal saline and lidocaine. The cold compress effect is provided for the perineum wound of a puerpera through the frozen medicine pad, the pain of the perineum wound is relieved, in addition, the medicine pad has the medicine effect, medicine treatment can be provided for the perineum wound of the puerpera, subtraction of perineum edema is facilitated, the double effects of cold compress and edema removal are achieved through combination of the medicine pad and the medicine pad, and the pain of the puerpera can be further relieved; the recovery of the perineum is accelerated.

The present invention provides the use of a reagent for detecting a target compound combination in the preparation of a detection agent, and the detection agent is used for screening and identifying whether a subject under test has taken drugs for treating vertigo, syncope or stroke, and assisting in determining whether the subject suffers from related diseases. Among them, the target compound combination includes one, several or all of lidocaine, cinepazide maleate, ticlopidine, penbutolol, fendiline, cinnarizine, clopidogrel, midodrine, dipyridamole, argatroban, rosuvastatin, atorvastatin, fluvastatin, and pitavastatin. The plasma sample pretreatment method of the present invention is simple, the detection and analysis time is short, the sensitivity of the method is high, and the types and quantities of detections are many; the method is divided into a primary screening method and a review method, which can improve the accuracy of the detection results and avoid false negative and false positive results.

The invention discloses a method for synchronously determining multiple drug components in a biological sample based on an LC-MS / MS. The multiple drugs are phenytoin sodium, paliperidone, voriconazole, theophylline, fluvoxamine and lidocaine, and the method comprises the following steps: obtaining the biological sample, and pre-treating the biological sample; according to the method, phenytoin sodium, paliperidone, voriconazole, theophylline, fluvoxamine and lidocaine in a sample are synchronously detected by adopting a liquid chromatography-mass spectrometry technology. The method provided by the invention can realize rapid and synchronous determination of phenytoin sodium, paliperidone, voriconazole, theophylline, fluvoxamine and lidocaine, and has high sensitivity and accuracy.

This invention discloses a bioactive glass and its preparation method, belonging to the field of bioactive glass technology. It aims to solve the problems of insufficient synergistic effect between antibacterial efficacy and bone-promoting activity in existing materials, as well as the inability to monitor in vivo degradation processes in real time. The bioactive glass comprises 44-48 parts silica; 22-27 parts calcium oxide; 22-27 parts sodium oxide; 5-7 parts phosphorus pentoxide; 2-4 parts europium zinc complex; 10-20 parts chitosan; 1-5 parts lidocaine; and 2-5 parts dilute acetic acid solution. The addition of the europium zinc complex promotes bone formation and enhances antibacterial activity, achieving a highly efficient synergy between anti-infection and tissue regeneration. Simultaneously, it provides optical tracking capabilities, allowing for non-destructive real-time monitoring of the material's degradation behavior and tissue integration in vivo via fluorescence imaging. This invention offers superior material performance and a simple preparation process, providing an innovative solution for the repair of infected bone defects.

The invention relates to the field of fine chemical engineering and application, in particular to a medicine clathrate eutectic crystal, a composition, a preparation method and application, and the medicine clathrate eutectic crystal comprises a medicine active component and a clathrate component wrapping the medicine active component; furthermore, the drug inclusion compound eutectic crystal is an inclusion compound eutectic crystal formed by lidocaine and cyclodextrin. According to the pharmaceutical inclusion compound eutectic or the pharmaceutical composition, the sustained release effect of the active pharmaceutical ingredients is obviously enhanced, and the pharmaceutical inclusion compound eutectic or the pharmaceutical composition can be used for preparing local anesthetics to prolong the anesthesia time and reduce the administration frequency.

The invention discloses a transdermal patch containing lidocaine, the transdermal patch comprises a polymer matrix layer, the polymer matrix layer comprises active ingredients lidocaine, an acrylic acid pressure-sensitive adhesive and a penetration enhancer, the weight content of the lidocaine is 21-33%, the weight content of the acrylic acid pressure-sensitive adhesive is 45-75%, the weight content of the penetration enhancer is 1-10%, and the weight content of the penetration enhancer is 1-10%. The weight content of the penetration enhancer is 3%-25%. The transdermal patch disclosed by the invention is simple in prescription and process, good in drug permeability and colloid application performance and high in stability, can be continuously used for a long time without causing skin irritation, and is suitable for treating peripheral nerve related pains, especially patients requiring long-term administration such as post-herpes zoster neuralgia.

The invention provides a preparation method of a novel 34G fat product, which comprises the following steps: S1, cleaning lidocaine, epinephrine medicine, red blood cells, grease and cell debris in a fat suction substance, and removing impurities; s2, performing chylification operation on the washed fat, performing chylification for 12-24 times back and forth, and controlling the time to be within 20-30 minutes; s3, enabling the chylified fat to pass through a sieve of 60 to 100 meshes; s4, putting the fat screened by the screen into an injector, and pushing the fat to pass through a 26-29G needle; and S5, sucking fat into an injector connected with a 26-29G needle, replacing the injector with a 34G needle, and pushing out the fat of the 34G needle to obtain the novel 34G fat product. The fat product provided by the invention contains fat cells, fat stem cells, endothelial cells, smooth muscle cells, fibroblasts, immune cells, progenitor cells and growth factors and proteins secreted by various fat, and can be used for beautifying and treating various skin diseases with non-treatment purposes.

The invention belongs to the field of medicine quality control, and particularly relates to a method for detecting N-nitroso-deethylidocaine genotoxic impurities in lidocaine. The method is realized by the following steps: firstly, preparing a test solution and a reference solution; and then, detecting by adopting a high performance liquid chromatography-triple quadrupole mass spectrometry method. The detection method provided by the invention can realize good quality control on lidocaine raw material medicines and preparations thereof, is strong in durability and high in detection sensitivity, can effectively avoid interference generated by a solvent, has a good impurity separation effect, can accurately detect toxic impurities in lidocaine, and is suitable for large-scale popularization and application. The method has the advantages of high sensitivity, strong specificity and good reproducibility. The detection method provided by the invention is simple and strong in operability.

The invention discloses a compound with a local anesthesia function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method of the compound comprises the following steps: mixing and heating lidocaine and 2-bromoethanol to obtain a compound 1; the preparation method comprises the following steps: mixing dicarboxylic acid, N-hydroxysuccinimide, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and a solvent to obtain a mixed solution; mixing and dissolving a compound 1, alkali and a solvent, and then adding into the mixed solution; and then carrying out spin-drying, separation and purification to obtain the compound with the local anesthesia function. The medicine can be used as a local anesthetic or analgesic for long-acting nerve block or selective nerve block. The medicine can block nerve conduction, has biocompatibility and biodegradability, is expected to overcome the problems of short time efficiency of single-needle injection and the like, and improves the efficacy of the medicine.

The pain relieving and disinfecting nursing bag comprises a sealed bag, lidocaine cotton swabs and iodophor cotton swabs, storage cavities are formed in the sealed bag, access openings are formed in the outer wall of the sealed bag, the access openings are communicated with the storage cavities, the storage cavities correspond to the lidocaine cotton swabs and the iodophor cotton swabs one to one, and the lidocaine cotton swabs and the iodophor cotton swabs are arranged in the sealed bag. And the lidocaine cotton swab and the iodophor cotton swab are correspondingly placed in the accommodating cavity. According to the technical scheme, in the time interval process of waiting for medicine absorption, a patient can be examined for other items in advance, reasonable utilization of time is ensured, the steps of pasting and removing do not need to be conducted, operation is easy, venipuncture efficiency is not affected, and the method is also suitable for people sensitive to skin and meanwhile can be used for disinfection before venipuncture.

An aqueous composition comprising lidocaine and at least two weak acids, each having at least one carboxylic acid group with a pKa of 2 to 5, wherein the aqueous composition has a pH of 3.5 to 4.1. The aqueous composition can further comprise phenylephrine HCl.

A stable liquid formulation for parenteral administration comprising lidocaine or a pharmaceutically acceptable salt thereof. The formulation comprises a low concentration of a sodium bicarbonate buffer in an aqueous solution having a pH of about 6.5 to about 7.2, sodium chloride, and optionally a pH adjusting agent. The liquid formulation is a stable formulation, supplied as a ready-to-use or finished product in a container or vial rich in carbon dioxide in the headspace.

The present invention relates to an injection composition for lipolysis, which is safe and effective, and more specifically, to an injection composition for lipolysis, which comprises: one or more compounds selected from the group consisting of hyaluronidase and pentoxifylline, and one or more compounds selected from the group consisting of hyaluronidase, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline and pentoxifylline. 5 to 10% (v / v) of carnitine (Carnitine); and lidocaine (Lidocaine); and normal saline. As a composition having both safety and efficacy, the injection composition for lipolysis of the present invention has an excellent lipolysis effect, does not cause a yo-yo phenomenon over time, and thus has a characteristic of not causing side effects such as skin depression.

The invention discloses a cross-linked collagen implant containing lidocaine and a preparation method of the cross-linked collagen implant, and mainly relates to the technical field of collagen. Compared with the prior art, the cross-linked collagen implant containing lidocaine has the advantages that natural collagen is modified through chemical cross-linking, and the collagen implant which is safe, durable, low in glutaraldehyde residue and low in cytotoxicity and contains anesthetic components is prepared by combining freeze-drying and sterile production processes. The invention also provides an application method of the lidocaine-containing cross-linked collagen implant, which is characterized in that the lidocaine-containing cross-linked collagen implant is injected into a corium layer and is used for correcting moderate and severe nasolabial cleavage wrinkles.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to external nano-emulsion gel for treating male erectile dysfunction and application of the external nano-emulsion gel. The invention provides external nano-emulsion gel for treating male erectile dysfunction. The external nano-emulsion gel is prepared from lidocaine, carbomer, a surfactant, a cosolvent and water, the particle size of the nanoemulsion gel is 80 nm to 120 nm, and the pH value of the nanoemulsion gel is 6.0 to 7.0; according to the nano-emulsion gel, the solubility and the skin penetrability of a hydrophobic drug lidocaine are remarkably improved through a micro-emulsion / nano-emulsion technology, so that the transdermal absorption efficiency is improved by 3.3-4.0 times, and quick effect taking and long-acting effects are realized. The carbomer gel matrix also provides good smearing performance and retention performance, the smearing area is increased by 5-6 times compared with that of common gel, and the use experience is remarkably improved.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

The invention relates to a compound external lotion based on lincomycin, which is characterized in that every two or three of lincomycin, lidocaine and vitamin B6 are compounded to form a multi-effect synergistic local treatment composition. The lotion takes an antibacterial effect as a core, integrates the functions of easing pain, relieving itching, resisting inflammation and repairing, and can synchronously solve the problems of skin infection, pain and barrier injury. Lincomycin efficiently inhibits pathogenic microorganisms, lidocaine quickly relieves pain and itching symptoms, vitamin B6 promotes epidermis repair and metabolic regulation, the lincomycin, lidocaine and vitamin B6 are scientifically matched to achieve complementary synergism, and every two of the lincomycin, lidocaine and vitamin B6 are simplified and combined to meet different clinical requirements. The dosage form design covers solution, gel and suspension dosage forms, has permeability, adhesiveness and stability, and is suitable for various skin lesions such as acute exudation and chronic wound surfaces. According to the scheme, the systemic side effects are reduced through local administration, and the treatment safety and the patient compliance are remarkably improved through optimization of low-irritation auxiliary materials.

The invention relates to the technical field of medicines, in particular to lidocaine ethosome gel as well as a preparation method and application thereof. The invention provides lidocaine ethosome gel. The lidocaine ethosome gel comprises the following components in percentage by weight: (a) 2-4% of lidocaine; (b) 5%-10% by weight of a film forming material; (c) 0.5%-2% by weight of a surfactant; (d) 0.01-1% by weight of an antioxidant; and (e) a solvent, wherein the solvent is selected from ethanol and water.

A method for providing a slide, wherein the method comprises the steps that: i) a base layer that is water and / or oxygen resistant is provided; ii) a layer comprising a bonding layer and a contact layer is coextruded to provide a coextruded layer; iii) the coextrusion layer is coated onto the base layer; iv) the coextruded layer coated onto the base layer is allowed to adhere to obtain a film resistant to aggressive chemicals, wherein the aggressive chemical is nicotine, fentanyl, lidocaine or rivastigmine, wherein the film comprises the coextruded layer formed from the bonding layer and the contact layer, which is coated onto the base layer, the bonding layer comprising at least one layer; and wherein the contact layer comprises a polymer having a RED value towards an aggressive chemical, namely nicotine, fentanyl, lidocaine or rivastigmine, based on the Hansen's solubility parameter (HSP) of > 0.8, more preferably a RED value in the range of 0.8 to 10, more preferably 0.8 to 5 and most preferably 1 to 2.

The invention discloses a compound preparation for treating blade throat and a preparation method thereof. The compound preparation is prepared from the following raw materials in parts by weight: 2-4 parts of lidocaine, 0.5-4 parts of borneol, 0.5-4 parts of menthol, 5-11 parts of fructus momordicae, 3-9 parts of fructus arctii, 6-12 parts of radix ophiopogonis, 2-8 parts of lily, 0.5-3 parts of fresh ginger, 1-5 parts of sodium carboxymethyl cellulose and 3-8 parts of cane sugar. The traditional Chinese medicine and the western medicine are matched for use, so that a rapid and completely effective analgesic effect is achieved, the analgesic duration is longer, meanwhile, the effects of detoxifying, relieving sore throat, promoting salivation, moistening lung, clearing away heart fire and tranquilizing are achieved, inflammation of the throat and the lung is eliminated, and a patient can recover rapidly without pain; the uneasiness of the patient caused by body discomfort is relieved, and the immunity of the patient is improved so as to reduce the recurrence probability.

Disclosed is a patch comprising an adhesive layer on a backing layer, wherein the adhesive layer comprises lidocaine or a pharmaceutically acceptable salt thereof, propylene glycol, a rubber adhesive base and a terpene resin, wherein the content of the lidocaine or a pharmaceutically acceptable salt thereof in the adhesive layer in terms of free form is 2 mass % to 6 mass % with respect to the total mass of the adhesive layer, wherein the ratio of the mass of the lidocaine or a pharmaceutically acceptable salt thereof in terms of free form to the mass of propylene glycol in the adhesive layer is 1:0.6 to 1:1.8, and wherein the content of the terpene resin in the adhesive layer is 5 mass % to 18 mass % with respect to a total mass of the adhesive layer.

The invention discloses an external antibacterial medicine composition as well as a preparation method and application thereof, and belongs to the technical field of antibacterial medicines. The external antibacterial pharmaceutical composition provided by the invention comprises a medicinal active component and a pharmaceutically acceptable carrier, wherein the medicinal active component comprises polymyxin B sulfate, trimethoprim sulfate and lidocaine; every 10 g of the antibacterial pharmaceutical composition for external use is prepared from the following components in parts by weight: 40000 to 60000 U of polymyxin B sulfate, 0.08 to 0.16 g of trimethoprim sulfate and 0.30 to 0.35 g of lidocaine. The pharmaceutical composition disclosed by the invention has broad-spectrum inhibition on multiple drug-resistant bacteria such as common gram-negative drug-resistant bacteria and acinetobacter baumannii on a wound surface, synchronously plays a synergistic role in relieving inflammatory response of the wound surface and relieving local pain, and remarkably improves the medication safety and the comprehensive treatment effect while ensuring excellent antibacterial activity.

The invention belongs to the technical field of pharmaceutical preparations, and particularly provides a lidocaine gel plaster and a method for improving the stability of the lidocaine gel plaster, only an antioxidant needs to be added into a medicine package, so that the medicine stability in the lidocaine gel plaster is high, the generation of impurities is effectively avoided or reduced, the impurity content can reach 0.09, and the lidocaine gel plaster has the advantages that the stability of the lidocaine gel plaster is improved; the medicine stability, the storage stability and the safety are higher.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

The invention discloses a temperature-sensitive modified chitosan hydrogel-loaded local anesthetic sustained-release analgesic system, a preparation method and an application. A temperature-sensitive chitosan derivative is dissolved in water at low temperature, a local anesthetic analgesic aqueous solution or a degradable polymer microsphere loaded with a local anesthetic analgesic is added in a liquid state and mixed evenly at low temperature, and the system is injected into a part requiring local anesthesia and analgesia to quickly form a gel at body temperature and release the drug slowly. The main features of the local anesthetic sustained-release analgesic composite hydrogel system are simple preparation, no organic solvent is used, and the local anesthetic analgesic can be slowly released, which solves the problem of the existing local anesthetics such as bupivacaine hydrochloride, ropivacaine and lidocaine being released too quickly and having a short action time; it can completely fill irregular wounds, has good biocompatibility and biodegradability, and is conducive to long-term local anesthesia, analgesia, anti-inflammatory and antipruritic effects and promotes wound healing.